title: PCP chemoprophylaxis is essential for lymphopenic dermatomyositis patients treated with immunomodulators.
authors.forename: Petros
authors.initials: P
authors.lastname: Efthimiou
authors.forename: Hiren
authors.initials: H
authors.lastname: Pokharna
authors.forename: Manil
authors.initials: M
authors.lastname: Kukar
authors.forename: Karen
authors.initials: K
authors.lastname: Hennessey
mesh_terms: D018890:Chemoprevention / Q000379:methods / Q000592:standards*; D003882:Dermatomyositis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000009:adverse effects / Q000627:therapeutic use*; D008231:Lymphopenia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D018836:Inflammation Mediators; D011241:Prednisone